BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Selcia Limited and Gilead Sciences, Inc. (GILD) Extend Liver Disease Drug Discovery Collaboration


11/29/2010 1:00:19 PM

Ongar, UK; 29 November 2010: Selcia Limited, a leading contract research organisation, today announced a drug discovery collaboration agreement with Gilead Sciences, Inc. (Foster City, California). Building on an established partnership following significant progress made to date, Selcia’s chemists and biologists will continue to provide integrated drug discovery services to support Gilead’s liver disease research programmes.

Dr. William Lee, Senior Vice President, Research at Gilead Sciences, commented: “We are pleased to announce the continued research collaboration with Selcia in this very important therapeutic area for Gilead. Scientists from both companies have interacted well together and have made successful progress against some difficult targets. We are looking forward to the collaboration delivering candidates for clinical studies in the foreseeable future”.

Commenting on the announcement, Selcia’s Managing Director, Dr. Hans Fliri said: “We are delighted to build on our strong collaborative relationship with Gilead in this challenging research area and important therapeutic indication. This represents a significant step forward in the development of Selcia’s Discovery services and further cements our position as a strategic and trusted partner for integrated drug discovery. We look forward to continuing to support Gilead in their search for new drugs to treat liver diseases and in fulfilling their longer term objectives”.

About Selcia Selcia Limited is a privately held contract research organisation with two operating divisions, Selcia Discovery and Selcia Radiolabelling, operating from a modern facility in Ongar, Essex, UK.

Selcia Discovery provides integrated drug discovery services to pharmaceutical and biotechnology industries; these services include in vitro biology, screening, fragment screening, medicinal, organic and analytical chemistry, and in vitro ADME/PK evaluation as well as in vivo PK (with a strategic partner). Selcia’s scientists act as integrated project teams within the customer group striving to produce viable drug candidates against its partners’ biological targets. Selcia’s expertise in capillary electrophoresis (CE) offers clients the benefits of a versatile and proven technology applied to drug discovery screening on a wide variety of targets. Its proprietary fragment screening service, CEfrag™ is a powerful application of the technique at the outset of a drug discovery programme.

For more information on Selcia Limited, please visit www.selcia.com

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information, please contact:

Selcia Limited: Dr Hans Fliri, Managing Director T: +44 (0)1277 367000 E: contact@selcia.com

Key Media Contact: Oliver Woodman-Smith Tel: +44 (0)117 9739224 E: oliver@syndicut.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES